BRAF and colorectal carcinoma: This study suggests that treatment with FTD-TPI in a selected subgroup of patients with relapsed BRAF-mutant CRC and good performance status may significantly prolong survival, providing an additional therapeutic option for this patient population with a poor prognosis.